Stock Financial Ratios, Dividends, Split History

CYH / Community Health Systems, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)332.61
Enterprise Value ($M)13,874.61
Book Value ($M)-767.00
Book Value / Share-6.66
Price / Book-0.43
NCAV ($M)-13,496.00
NCAV / Share-116.05
Price / NCAV-0.02
Share Statistics
Common Shares Outstanding 114,627,148
Weighted Average Number Of Diluted Shares Outstanding 111,769,821
Common Stock Shares Outstanding 114,651,004
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Shares Outstanding Basic 111,769,821
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.18
Return on Assets (ROA)-0.11
Return on Equity (ROE)-1.48
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio1.76
Income Statement (mra) ($M)
Disposal Group Including Discontinued Operation Revenue79,000,000.00
Health Care Organization Patient Service Revenue Provisionfor Bad Debts3,045,000,000.00
Health Care Organization Revenue Net Of Patient Service Revenue Provisions15,353,000,000.00
Health Care Organization Revenue18,398,000,000.00
Operating Income-1,878.00
Net Income-2,396.00
Earnings Per Share Basic-22.00
Earnings Per Share Diluted-22.00
Cash Flow Statement (mra) ($M)
Cash From Operations773.00
Cash from Investing1,069.00
Cash from Financing1,069.00
Identifiers and Descriptors
Central Index Key (CIK)1108109
Related CUSIPS
203668116 203668958 203668908

Split History

Stock splits are used by Community Health Systems, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

4h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

5h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

American Airlines, MiMedx Tumble into Tuesday’s 52-Week Low Club

2018-07-03 247wallst
July 3, 2018: Here are four stocks trading with heavy volume among 43 equities making new 52-week lows in Tuesday’s shortened session. On the NYSE advancers led decliners by about 1.69 to 1 and on the Nasdaq, advancers led decliners by about 1.2 to 1. (60-1)

Community Health, Frontier Communications Dive Friday’s 52-Week Low Club

2018-06-29 247wallst
June 29, 2018: Here are four stocks trading with heavy volume among 96 equities making new 52-week lows in Friday’s session. On the NYSE advancers led decliners by about 1.4 to 1 and on the Nasdaq, advancers led decliners by about 1.19 to 1. (30-1)

Community Health Arm to Divest AllianceHealth Deaconess

2018-06-27 zacks
Community Health Systems, Inc. (CYH - Free Report) recently announced that one of its units has signed a definitive agreement to sell 291-bed AllianceHealth Deaconess hospital in Oklahoma City, OK along with other related businesses to a subsidiary of INTEGRIS Health. The transaction is expected to close in the third quarter of 2018, subject to customary regulatory approvals and closing conditions. (64-0)

Community Health's Ratings Downgraded by Moody's

2018-06-21 zacks
Credit rating giant Moody’s Investors Service recently downgraded the ratings of Community Health Systems (CYH - Free Report) . The ratings include Corporate Family Rating (CFR), which were lowered to Caa2 from Caa1 and the Probability of Default Rating (PDR), which deteriorated to Caa2-PD/LD from Caa1-PD. The ratings outlook remains stable. The above was based on the company’s announcement of the final results of its debt exchange wherein holders exchanged part of unsecured notes due 2019, 2020 and 2022 for new junior lien notes due 2023 and 2024. (62-1)

Earnings or Revenue-Weighted ETFs: Who Won in Q1?

2018-06-12 zacks
We are at the end of the Q1 earnings season. As of now, 98.6% of the S&P 500 companies have reported earnings for Q1, with a 24.3% year-over-year jump on 8.7% revenue growth. Almost 76.9% of the companies beat on earnings while 74.4% beat on revenues, per the Earnings Trends issued on May 31. (103-0)

CUSIP: 203668108